FAK and Nanog cross talk with p53 in cancer stem cells

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 4, 2013, Pages 576-580

  Golubovskaya, Vita M ^a,b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Adhesion; Cancer; Focal adhesion kinase; Inhibitor; Metastasis; Tumor

Indexed keywords

FOCAL ADHESION KINASE; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN MDM2; PROTEIN P53; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

APOPTOSIS; CANCER STEM CELL; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL INVASION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; EPIGENETICS; HUMAN; PLURIPOTENT STEM CELL; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL NICHE; TUMOR MICROENVIRONMENT;

ANIMALS; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HOMEODOMAIN PROTEINS; HUMANS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84876736201     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520611313040006     Document Type: Review

References (46)

1. Akhtar, K.; Bussen, W.; Scott, S. P. Cancer stem cells from initiation to elimination, how far have we reached? (Review). Int. J. Oncol., 2009, 34, 1491-1503.
2. Bhaijee, F.; Pepper, D. J.; Pitman, K. T.; Bell, D. Cancer stem cells in head and neck squamous cell carcinoma: A review of current knowledge and future applications. Head Neck, 2011[Epub ahead of print].
3. Scheel, C.; Weinberg, R. A. Phenotypic plasticity and epithelialmesenchymal transitions in cancer and normal stem cells? Int. J. Cancer, 2011, 129, 2310-2314.
4. Lapidot, T.; Sirard, C.; Vormoor, J.; Murdoch, B.; Hoang, T.; Caceres-Cortes, J.; Minden, M., Paterson, B., Caligiuri, M. A. and Dick, J. E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 1994, 367, 645-648
5. Ignatova, T. N.; Kukekov, V. G.; Laywell, E. D.; Suslov, O. N.; Vrionis, F. D.; Steindler, D. A. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia., 2002, 39, 193-206.
6. Singh, S. K.; Hawkins, C.; Clarke, I. D.; Squire, J. A.; Bayani, J.; Hide, T.; Henkelman, R. M.; Cusimano, M. D.; Dirks, P. B. Identification of human brain tumour initiating cells. Nature, 2004, 432, 396-401.
7. Hermann, P. C.; Huber, S. L.; Herrler, T.; Aicher, A.; Ellwart, J. W.; Guba, M.; Bruns, C. J.; Heeschen, C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell. Stem. Cell, 2007, 1, 313-323.
8. Tirino, V.; Camerlingo, R.; Franco, R.; Malanga, D.; La Rocca, A.; Viglietto, G.; Rocco, G.; Pirozzi, G. The role of CD133 in the identification and characterisation of tumour-initiating cells in nonsmall-cell lung cancer. Eur. J. Cardiothorac. Surg., 2009, 36, 446-453.
9. Patrawala, L.; Calhoun-Davis, T.; Schneider-Broussard, R.; Tang, D. G. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res., 2007, 67, 6796-6805.
10. Scheel, C.; Weinberg, R. A. Cancer stem cells and epithelialmesenchymal transition: Concepts and molecular links. Semin Cancer Biol., 2012, [Epub ahead of print].
11. Li, Y.; Laterra, J. Cancer stem cells: distinct entities or dynamically regulated phenotypes? Cancer Res., 2012, 72, 576-580.
12. Ho, B.; Olson, G.; Figel, S.; Gelman, I.; Cance, W.; Golubovskaya, V. Nanog increases focal adhesion kinase (FAK) promoter activity and expression and directly binds to FAK protein to be phosphorylated. J. Biol. Chem., 2012, [Epub ahead of print].
13. Chambers, I.; Colby, D.; Robertson, M.; Nichols, J.; Lee, S.; Tweedie, S.; Smith, A. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell, 2003, 113, 643-655.
14. Mitsui, K.; Tokuzawa, Y.; Itoh, H.; Segawa, K.; Murakami, M.; Takahashi, K.; Maruyama, M.; Maeda, M.; Yamanaka, S. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell, 2003, 113, 631-642.
15. Jeter, C. R.; Liu, B.; Liu, X.; Chen, X.; Liu, C.; Calhoun-Davis, T.; Repass, J.; Zaehres, H.; Shen, J. J.; Tang, D. G. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene, 2011, 30, 3833-3845.
16. Theunissen, T. W.; Silva, J. C. Switching on pluripotency: a perspective on the biological requirement of Nanog. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 2011, 366, 2222-2229.
17. Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 2007, 131, 861-872.
18. Lin, T.; Chao, C.; Saito, S.; Mazur, S. J.; Murphy, M. E.; Appella, E.; Xu, Y. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat. Cell Biol., 2005, 7, 165-171.
19. Krizhanovsky, V.; Lowe, S. W. Stem cells: The promises and perils of p53. Nature, 2009, 460, 1085-1086.
20. Hong, H.; Takahashi, K.; Ichisaka, T.; Aoi, T.; Kanagawa, O.; Nakagawa, M.; Okita, K.; Yamanaka, S. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature, 2009, 460, 1132-1135
21. Kawamura, T.; Suzuki, J.; Wang, Y. V.; Menendez, S.; Morera, L. B.; Raya, A.; Wahl, G. M.; Izpisua Belmonte, J. C. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature, 2009, 460, 1140-1144
22. Marion, R. M.; Strati, K.; Li, H.; Murga, M.; Blanco, R.; Ortega, S.; Fernandez-Capetillo, O.; Serrano, M.; Blasco, M. A. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature, 2009, 460, 1149-1153.
23. Kwon, S.; Jun, E. K.; Kim, A.; Whang, K. Y.; Kim, H.; Oh, S.; Yoon, B. S.; You, S. Nanog-induced dedifferentiation of p53-deficient mouse astrocytes into brain cancer stem-like cells. Biochem. Biophys. Res. Commun., 2011, 412, 175-181.
24. Po, A.; Ferretti, E.; Miele, E.; De Smaele, E.; Paganelli, A.; Canettieri, G.; Coni, S.; Di Marcotullio, L.; Biffoni, M.; Massimi, L.; Di Rocco, C.; Screpanti, I.; Gulino, A. Hedgehog controls neural stem cells through p53-independent regulation of Nanog. EMBO J., 2010, 29, 2646-2658.
25. Golubovskaya, V. M. Targeting focal adhesion kinase in cancer part I. Anticancer Agents Med. Chem., 2010, 10, 713.
26. Hanks, S. K.; Calalb, M. B.; Harper, M. C.; Patel, S. K. Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin. Proc. Natl. Acad. Sci. USA., 1992, 89, 8487-8491.
27. Golubovskaya, V. M.; Cance, W. G. FAK and P53 Protein Interactions. Anticancer Agents Med. Chem., 2011, 11, 617-619.
28. Lark, A. L.; Livasy, C. A.; Calvo, B.; Caskey, L.; Moore, D. T.; Yang, X.; Cance, W. G. Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses. Clin. Cancer Res., 2003, 9, 215-222.
29. Hochwald, S. N.; Nyberg, C.; Zheng, M.; Zheng, D.; Wood, C.; Massoll, N. A.; Magis, A.; Ostrov, D.; Cance, W. G.; Golubovskaya, V. M. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle., 2009, 8, 2435-2443.
30. Golubovskaya, V. M.; Nyberg, C.; Zheng, M.; Kweh, F.; Magis, A.; Ostrov, D.; Cance, W. G. A Small Molecule Inhibitor, 1,2,4,5-Benzenetetraamine Tetrahydrochloride, Targeting the Y397 Site of Focal Adhesion Kinase Decreases Tumor Growth. J. Med. Chem., 2008, 51, 7405-7416.
31. Beierle, E. A.; Ma, X.; Stewart, J.; Nyberg, C.; Trujillo, A.; Cance, W. G.; Golubovskaya, V. M. Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma. Cell Cycle., 2010; 9, 1005-1015.
32. Golubovskaya, V. M. Focal adhesion kinase as a cancer therapy target. Anticancer Agents Med. Chem., 2010, 10, 735-741.
33. Golubovskaya, V.; Kaur, A.; Cance, W. Cloning and characterization of the promoter region of human focal adhesion kinase gene: nuclear factor kappa B and p53 binding sites. Biochim. Biophys. Acta., 2004, 1678, 111-125.
34. Golubovskaya, V. M.; Finch, R.; Kweh, F.; Massoll, N. A.; Campbell-Thompson, M.; Wallace, M. R.; Cance, W. G. p53 regulates FAK expression in human tumor cells. Mol. Carcinog., 2008, 47, 373-382.
35. Golubovskaya, V. M.; Conway-Dorsey, K.; Edmiston, S. N.; Tse, C. K.; Lark, A. A.; Livasy, C. A.; Moore, D.; Millikan, R. C.; Cance, W. G. FAK overexpression and p53 mutations are highly correlated in human breast cancer. Int. J. Cancer, 2009, 125, 1735-1738.
36. Golubovskaya, V. M.; Finch, R.; Cance, W. G. Direct Interaction of the N-terminal Domain of Focal Adhesion Kinase with the N-terminal Transactivation Domain of p53. J. Biol. Chem., 2005, 280, 25008-25021.
37. Lim, S. T.; Chen, X. L.; Lim, Y.; Hanson, D. A.; Vo, T. T.; Howerton, K.; Larocque, N.; Fisher, S. J.; Schlaepfer, D. D.; Ilic, D. Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol. Cell., 2008, 29, 9-22.
38. Cance, W. G.; Golubovskaya, V. M. Focal adhesion kinase versus p53: apoptosis or survival? Sci. Signal. 2008, 1, pe22.
39. Luo, M., Fan, H., Nagy, T., Wei, H., Wang, C., Liu, S., Wicha, M. S. and Guan, J. L. (2009) Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res., 2009, 69, 466-474.
40. Fan, H.; Guan, J. L. Compensatory function of Pyk2 protein in the promotion of focal adhesion kinase (FAK)-null mammary cancer stem cell tumorigenicity and metastatic activity. J. Biol. Chem., 2011, 286, 18573-18582.
41. Gao, H.; Priebe, W.; Glod, J.; Banerjee, D. Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell conditioned medium. Stem Cells, 2009, 27, 857-865.
42. Kobayashi, K.; Takahashi, H.; Inoue, A.; Harada, H.; Toshimori, S.; Kobayashi, Y.; Goto, K.; Sugimoto, K.; Yano, H., Ohnishi, T. and Tanaka, J. Oct-3/4 promotes migration and invasion of glioblastoma cells. J. Cell. Biochem. 2012, 113, 508-517.
43. Wang, S. D.; Rath, P.; Lal, B.; Richard, J. P.; Li, Y.; Goodwin, C. R.; Laterra, J.; Xia, S. EphB2 receptor controls proliferation/ migration dichotomy of glioblastoma by interacting with focal adhesion kinase. Oncogene, 2012, [Epub ahead of print].
44. Schober, M.; Fuchs, E. Tumor-initiating stem cells of squamous cell carcinomas and their control by TGF-beta and integrin/focal adhesion kinase (FAK) signaling. Proc. Natl. Acad. Sci. U S A., 2011, 108, 10544-10549.
45. Shibue, T.; Weinberg, R. A. Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc. Natl. Acad. Sci. U S A., 2009, 106, 10290-10295.
46. Shibue, T.; Weinberg, R. A. Metastatic colonization: settlement, adaptation and propagation of tumor cells in a foreign tissue environment. Semin. Cancer Biol., 2011, 21, 99-106.